Immunobiologics in the treatment of psoriasis
The pathogenesis of various inflammatory cutaneous diseases such as psoriasis, atopic dermatitis and mycosis fungoides relies greatly on the abnormal function of T cells. Fundamental knowledge of the role of T cells in the cutaneous immune response has led to the development and production of biolog...
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 123(2007), 2 vom: 20. Mai, Seite 129-38 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | |
| Format: | Article |
| Langue: | English |
| Publié: |
2007
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Review Antibodies, Monoclonal Dermatologic Agents Immunoglobulin G Receptors, Tumor Necrosis Factor Recombinant Fusion Proteins Alefacept ELK3V90G6C Etanercept |
| Résumé: | The pathogenesis of various inflammatory cutaneous diseases such as psoriasis, atopic dermatitis and mycosis fungoides relies greatly on the abnormal function of T cells. Fundamental knowledge of the role of T cells in the cutaneous immune response has led to the development and production of biologic molecules designed to block T cell function at various steps, specifically activation (i.e. alefacept, efalizumab), trafficking into inflamed skin (i.e. efalizumab) and effector function under cytokine control (i.e. etanercept, infliximab, adalimumab, and anti-IL-12 antibody). We review the immune abnormalities and the role of T cells in psoriasis, and the recent biologic therapies, which share the common mission to hinder T cell activity in inflammatory diseases. An advantage from the preciseness of these biologic therapies is the potential limit of non-specific and potentially devastating organ toxicity, which commonly plagues other systemic therapies |
|---|---|
| Description: | Date Completed 26.06.2007 Date Revised 29.05.2025 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |